Filing Details
- Accession Number:
- 0001209191-22-027651
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-06 17:09:58
- Reporting Period:
- 2022-04-14
- Accepted Time:
- 2022-05-06 17:09:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1087294 | Cumberland Pharmaceuticals Inc | CPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1684087 | Caroline Young | 2525 West End Avenue Suite 950 Nashville TN 37203 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-04-14 | 19 | $2.71 | 15,796 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-18 | 19 | $2.63 | 15,815 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-19 | 19 | $2.69 | 15,834 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-20 | 19 | $2.74 | 15,853 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-21 | 19 | $2.75 | 15,872 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-22 | 19 | $2.73 | 15,891 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-25 | 20 | $2.62 | 15,911 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-26 | 20 | $2.53 | 15,931 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-27 | 20 | $2.41 | 15,951 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-28 | 20 | $2.51 | 15,971 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-29 | 20 | $2.44 | 15,991 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.